Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stake Lessened by Macquarie Group Ltd.

Posted by Defense World Staff on Mar 9th, 2023

Macquarie Group Ltd. decreased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) by 62.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,363 shares of the specialty pharmaceutical company’s stock after selling 45,046 shares during the quarter. Macquarie Group Ltd.’s holdings in Jazz Pharmaceuticals were worth $3,648,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of JAZZ. Captrust Financial Advisors boosted its holdings in shares of Jazz Pharmaceuticals by 2.4% during the first quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock worth $577,000 after purchasing an additional 86 shares during the period. Securian Asset Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 1.8% during the 3rd quarter. Securian Asset Management Inc. now owns 5,781 shares of the specialty pharmaceutical company’s stock worth $771,000 after purchasing an additional 100 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Jazz Pharmaceuticals by 90.3% during the 3rd quarter. Quadrant Capital Group LLC now owns 215 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 102 shares during the last quarter. Great Lakes Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 7.5% in the 3rd quarter. Great Lakes Advisors LLC now owns 1,586 shares of the specialty pharmaceutical company’s stock valued at $211,000 after buying an additional 110 shares in the last quarter. Finally, Boston Partners increased its holdings in Jazz Pharmaceuticals by 2.1% in the third quarter. Boston Partners now owns 5,643 shares of the specialty pharmaceutical company’s stock worth $752,000 after buying an additional 114 shares during the last quarter. 89.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on JAZZ. HC Wainwright restated a “buy” rating and set a $204.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday. Royal Bank of Canada increased their price objective on Jazz Pharmaceuticals from $206.00 to $207.00 and gave the company an “outperform” rating in a report on Thursday, November 10th. StockNews.com cut Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. The Goldman Sachs Group upped their price objective on shares of Jazz Pharmaceuticals from $190.00 to $212.00 and gave the company a “buy” rating in a research report on Friday, March 3rd. Finally, Needham & Company LLC lowered their price objective on Jazz Pharmaceuticals from $210.00 to $205.00 and set a “buy” rating on the stock in a research report on Thursday, March 2nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $204.27.

Jazz Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ JAZZ opened at $139.83 on Thursday. Jazz Pharmaceuticals plc has a 1-year low of $125.36 and a 1-year high of $169.98. The company has a current ratio of 2.79, a quick ratio of 2.03 and a debt-to-equity ratio of 1.85. The company has a 50-day moving average of $151.76 and a two-hundred day moving average of $148.39. The company has a market cap of $8.86 billion, a PE ratio of -39.39, a P/E/G ratio of 0.82 and a beta of 0.73.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, SVP Samantha Pearce sold 531 shares of the stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $155.45, for a total value of $82,543.95. Following the transaction, the senior vice president now directly owns 11,309 shares in the company, valued at approximately $1,757,984.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Samantha Pearce sold 531 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $155.45, for a total value of $82,543.95. Following the transaction, the senior vice president now owns 11,309 shares in the company, valued at $1,757,984.05. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Patricia Carr sold 1,148 shares of the business’s stock in a transaction dated Sunday, March 5th. The stock was sold at an average price of $140.76, for a total value of $161,592.48. Following the sale, the chief accounting officer now directly owns 7,309 shares of the company’s stock, valued at $1,028,814.84. The disclosure for this sale can be found here. Insiders sold 12,395 shares of company stock worth $1,910,816 in the last quarter. Insiders own 4.40% of the company’s stock.

About Jazz Pharmaceuticals

(Get Rating)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.